798569-33-2
Chemical Structure
HD5
- CAS. Nr.: 798569-33-2
- Formula:C144H238N50O45S6
- Molecular Weight:3582.14
SMILES: C([C@H]1C(=O)N[C@@]2(C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@]([C@@H](C)O)(C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@]3(CSSC[C@@](C(=O)N[C@H](C(N[C@@H](CCCNC(=N)N)C(O)=O)=O)CSSC[C@H](NC([C@@H](NC([C@H](C)N)=O)[C@@H](C)O)=O)C(=O)N1)(NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC4=CC=C(O)C=C4)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@]([C@H](CC)C)(NC(=O)[C@H](CCC(O)=O)NC(=O)[C@](CSSC2)(NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@]([C@@H](C)O)(NC(=O)[C@H](C)NC3=O)[H])[H])[H])[H])[H])[H])[H])C5=CC=C(O)C=C5
Biological Activity: HD5 is an innate immune effector peptide and SARS-CoV Inhibitor. HD5 binds to the ligand-binding domain of angiotensin-converting enzyme-2 (ACE2) via multiple hydrogen bonds to competitively block the receptor, shielding it from viral recognition. HD5 can be used for the research of COVID-19, HPV16 infection, epithelial ovarian cancer, small-cell lung cancer, and colon cancer[1][2][3].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
HD5 | HD5 is an innate immune effector peptide and SARS-CoV Inhibitor. HD5 binds to the ligand-binding domain of angiotensin-converting enzyme-2 (ACE2) via multiple hydrogen bonds to competitively block the receptor, shielding it from viral recognition. HD5 can be used for the research of COVID-19, HPV16 infection, epithelial ovarian cancer, small-cell lung cancer, and colon cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Mahendran ASK, et al. The Potential of Antiviral Peptides as COVID-19 Therapeutics. Front Pharmacol. 2020 Sep 15;11:575444. [Content Brief]
- [2]. Gulati NM, et al. α-Defensin HD5 Stabilizes Human Papillomavirus 16 Capsid/Core Interactions. Pathog Immun. 2019 Sep 12;4(2):196-234. [Content Brief]
- [3]. Vragniau C, et al. Studies on the Interaction of Tumor-Derived HD5 Alpha Defensins with Adenoviruses and Implications for Oncolytic Adenovirus Therapy. J Virol. 2017;91(6):e02030-16. Published 2017 Feb 28. [Content Brief]
